"About eight to 10 (from the 15), I would say, will be oral contraceptives," Vinita Gupta, chief executive of Lupin's U.S. unit, told Reuters.
Lupin has launched five products in the U.S. this fiscal year.
The drugmaker had said earlier its September quarter net profit rose 9 percent to 2.91 billion rupees to beat analyst estimates.
0 comments:
Post a Comment
Let Us Know Your Opinion!